Cargando…
Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic
INTRODUCTION: During the pandemic, smokers who wished to access support to quit faced additional barriers. A smoking cessation service which utilized pharmacist independent prescribers working within community pharmacy was implemented. Clients received behavioral advice via a consultation with an ad...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID)
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603824/ https://www.ncbi.nlm.nih.gov/pubmed/37901881 http://dx.doi.org/10.18332/tid/170580 |
_version_ | 1785126687972786176 |
---|---|
author | Thomas, Trudy Sykes, Bronte Shah, Shilpa Corlett, Sarah |
author_facet | Thomas, Trudy Sykes, Bronte Shah, Shilpa Corlett, Sarah |
author_sort | Thomas, Trudy |
collection | PubMed |
description | INTRODUCTION: During the pandemic, smokers who wished to access support to quit faced additional barriers. A smoking cessation service which utilized pharmacist independent prescribers working within community pharmacy was implemented. Clients received behavioral advice via a consultation with an advisor and then three consultations with a pharmacist, who prescribed varenicline, where appropriate. Consultations were by phone or video. This evaluation assessed the self-reported outcomes and experiences of clients and pharmacists. METHODS: A mixed-methods approach was used involving both on-line questionnaires to clients and interviews with a sample of questionnaire respondents and participating prescribing pharmacists. RESULTS: The questionnaire was completed by 85 clients with 59% reporting they had quit. Eleven clients and seven out of eight pharmacists were interviewed. Varenicline had been received by 96% of clients. The best aspects of the service reported by clients in the questionnaire and at interview were support received from the pharmacist and ease of access to varenicline. Clients regarded the service as being ‘safe’ to access during the pandemic. Nearly three-quarters of client respondents (72%) stated no service improvements were required. However, national supply challenges made collection of varenicline from the nominated pharmacy an issue. Some clients experienced a long wait-time before accessing the service. For pharmacists, the service offered flexibility including the opportunity to contact clients ‘out of office’ hours without distractions. However, not being physically in the pharmacy could result in them not being able to access the client’s medicine history. Pharmacists identified that remote consultations were not ideal for all clients. CONCLUSIONS: Pharmacist prescribers can deliver effective smoking cessation services through remote consultations. Greater flexibility would allow the service to be tailored to the client’s need. |
format | Online Article Text |
id | pubmed-10603824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID) |
record_format | MEDLINE/PubMed |
spelling | pubmed-106038242023-10-28 Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic Thomas, Trudy Sykes, Bronte Shah, Shilpa Corlett, Sarah Tob Induc Dis Research Paper INTRODUCTION: During the pandemic, smokers who wished to access support to quit faced additional barriers. A smoking cessation service which utilized pharmacist independent prescribers working within community pharmacy was implemented. Clients received behavioral advice via a consultation with an advisor and then three consultations with a pharmacist, who prescribed varenicline, where appropriate. Consultations were by phone or video. This evaluation assessed the self-reported outcomes and experiences of clients and pharmacists. METHODS: A mixed-methods approach was used involving both on-line questionnaires to clients and interviews with a sample of questionnaire respondents and participating prescribing pharmacists. RESULTS: The questionnaire was completed by 85 clients with 59% reporting they had quit. Eleven clients and seven out of eight pharmacists were interviewed. Varenicline had been received by 96% of clients. The best aspects of the service reported by clients in the questionnaire and at interview were support received from the pharmacist and ease of access to varenicline. Clients regarded the service as being ‘safe’ to access during the pandemic. Nearly three-quarters of client respondents (72%) stated no service improvements were required. However, national supply challenges made collection of varenicline from the nominated pharmacy an issue. Some clients experienced a long wait-time before accessing the service. For pharmacists, the service offered flexibility including the opportunity to contact clients ‘out of office’ hours without distractions. However, not being physically in the pharmacy could result in them not being able to access the client’s medicine history. Pharmacists identified that remote consultations were not ideal for all clients. CONCLUSIONS: Pharmacist prescribers can deliver effective smoking cessation services through remote consultations. Greater flexibility would allow the service to be tailored to the client’s need. European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID) 2023-10-27 /pmc/articles/PMC10603824/ /pubmed/37901881 http://dx.doi.org/10.18332/tid/170580 Text en © 2023 Thomas T. et al. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License. |
spellingShingle | Research Paper Thomas, Trudy Sykes, Bronte Shah, Shilpa Corlett, Sarah Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic |
title | Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic |
title_full | Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic |
title_fullStr | Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic |
title_full_unstemmed | Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic |
title_short | Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic |
title_sort | pharmacist prescriber smoking cessation intervention during the covid-19 pandemic |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603824/ https://www.ncbi.nlm.nih.gov/pubmed/37901881 http://dx.doi.org/10.18332/tid/170580 |
work_keys_str_mv | AT thomastrudy pharmacistprescribersmokingcessationinterventionduringthecovid19pandemic AT sykesbronte pharmacistprescribersmokingcessationinterventionduringthecovid19pandemic AT shahshilpa pharmacistprescribersmokingcessationinterventionduringthecovid19pandemic AT corlettsarah pharmacistprescribersmokingcessationinterventionduringthecovid19pandemic |